For patients facing life-threatening pulmonary embolism with right heart strain, the clinical calculus has long been uncomfortable: systemic thrombolytics carry serious bleeding risk, while anticoagulation alone may leave the overburdened right ventricle struggling. The BETULA trial tests whether a leaner, faster catheter-directed approach can thread that needle.
This open-label randomized controlled trial enrolled 60 patients with acute intermediate-high-risk PE between 2020 and 2024, assigning them 1:1 to either a low-dose catheter-directed thrombolysis (CDT) protocol — delivering just 4 mg of recombinant tissue plasminogen activator per catheter over a compressed two-hour infusion window — plus unfractionated heparin, or heparin alone. The primary endpoint, change in right ventricular to left ventricular diameter ratio at 24 hours, favored CDT meaningfully: a reduction of 0.17 versus an increase of 0.02 in the heparin-only arm (p=0.01). Secondary outcomes including thrombus burden, echocardiographic RV function markers, hospital stay, 30-day mortality, and 90-day recurrent PE did not differ significantly between groups, and only one death occurred — in the heparin cohort.
The broader context matters here. Previous landmark CDT trials such as ULTIMA and SEATTLE II used ultrasound-assisted catheters and substantially higher thrombolytic doses over longer infusions — approaches that drive up cost and procedural complexity, constraining real-world adoption. BETULA's stripped-down protocol is a deliberate departure, suggesting that meaningful RV decompression may be achievable without full-dose, ultrasound-facilitated delivery. That said, the trial's limitations are significant: at just 58 evaluable patients, it is dramatically underpowered to detect differences in clinical outcomes like mortality or recurrence. The open-label design introduces potential measurement bias, and the two-hour endpoint for the primary measure leaves durability questions open. This is best characterized as a proof-of-concept signal — intriguing enough to justify a larger, adequately powered trial, but not yet practice-changing on its own.